JP2018522592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522592A5 JP2018522592A5 JP2018524548A JP2018524548A JP2018522592A5 JP 2018522592 A5 JP2018522592 A5 JP 2018522592A5 JP 2018524548 A JP2018524548 A JP 2018524548A JP 2018524548 A JP2018524548 A JP 2018524548A JP 2018522592 A5 JP2018522592 A5 JP 2018522592A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cell line
- human
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112019A JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112020A JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15178899 | 2015-07-29 | ||
| EP15178899.9 | 2015-07-29 | ||
| GBGB1603655.0A GB201603655D0 (en) | 2016-03-02 | 2016-03-02 | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| GB1603655.0 | 2016-03-02 | ||
| GB201605457 | 2016-03-31 | ||
| GB1605457.9 | 2016-03-31 | ||
| GB1610164.4 | 2016-06-10 | ||
| GBGB1610164.4A GB201610164D0 (en) | 2016-06-10 | 2016-06-10 | Modified natural killer cells and natural killer cell lines having increased cytoxicity |
| PCT/EP2016/068001 WO2017017184A1 (en) | 2015-07-29 | 2016-07-28 | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112019A Division JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112020A Division JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522592A JP2018522592A (ja) | 2018-08-16 |
| JP2018522592A5 true JP2018522592A5 (enExample) | 2019-12-19 |
| JP6974681B2 JP6974681B2 (ja) | 2021-12-01 |
Family
ID=56683913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524548A Active JP6974681B2 (ja) | 2015-07-29 | 2016-07-28 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112020A Active JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112019A Pending JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112020A Active JP7359346B2 (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP2021112019A Pending JP2021178824A (ja) | 2015-07-29 | 2021-07-06 | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10034925B2 (enExample) |
| EP (6) | EP3828266B1 (enExample) |
| JP (3) | JP6974681B2 (enExample) |
| KR (1) | KR20180028530A (enExample) |
| CN (3) | CN116064400B (enExample) |
| AU (2) | AU2016300128B2 (enExample) |
| BR (1) | BR112018001660A2 (enExample) |
| CA (2) | CA3156128A1 (enExample) |
| DK (3) | DK3434762T3 (enExample) |
| ES (5) | ES2876938T3 (enExample) |
| HK (1) | HK1252582B (enExample) |
| MX (2) | MX380813B (enExample) |
| WO (1) | WO2017017184A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| EP3828266B1 (en) * | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3581190B1 (en) | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| CN110168078B (zh) * | 2017-01-06 | 2024-05-14 | 免疫生物公司 | 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞 |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| DE102017002645A1 (de) * | 2017-03-17 | 2018-09-20 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen |
| WO2019016360A1 (en) * | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
| CA3069557A1 (en) * | 2017-07-21 | 2019-01-24 | Cellectis | Engineered immune cells resistant to tumor microoenvironment |
| US20200392458A1 (en) * | 2017-11-24 | 2020-12-17 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| AU2019271366B2 (en) * | 2018-05-16 | 2026-02-26 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins |
| US12692308B2 (en) | 2018-06-06 | 2026-07-28 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for cell enrichment |
| CN108743595B (zh) * | 2018-06-08 | 2020-11-27 | 厦门诺康得生物科技有限公司 | 一种nk细胞免疫检查点抑制剂及其制备方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| AU2019386140B2 (en) | 2018-11-28 | 2026-05-28 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| BR112021016046A2 (pt) * | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| CN109908155A (zh) * | 2019-03-11 | 2019-06-21 | 上海中医药大学 | 丹参酮ⅱa的药物用途 |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| JP2022526504A (ja) * | 2019-03-21 | 2022-05-25 | オーエヌケー セラピューティクス リミテッド | 細胞死に対する耐性が増大した改変免疫エフェクター細胞 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| RU2731293C1 (ru) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний |
| EP3789485A1 (en) * | 2019-09-06 | 2021-03-10 | ONK Therapeutics Limited | Cellular therapies for cancer |
| JP7689949B2 (ja) | 2019-10-03 | 2025-06-09 | アーティサン ディベロップメント ラブズ インコーポレイテッド | 操作されたデュアルガイド核酸を有するｃｒｉｓｐｒシステム |
| CN111849896B (zh) * | 2020-07-31 | 2022-07-01 | 广东昭泰体内生物医药科技有限公司 | 一种car-nk细胞培养基及其应用 |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| AU2022227650A1 (en) | 2021-02-25 | 2023-10-12 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| WO2022256448A2 (en) | 2021-06-01 | 2022-12-08 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| JP2024522756A (ja) * | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| CA3223311A1 (en) | 2021-06-18 | 2022-12-22 | Andrea BARGHETTI | Compositions and methods for targeting, editing or modifying human genes |
| CN113684180B (zh) * | 2021-08-31 | 2023-05-26 | 山东大学第二医院 | 一种提高骨髓瘤杀伤活性的nk细胞制备方法 |
| CN114544971B (zh) * | 2022-02-22 | 2024-08-30 | 广东省科学院动物研究所 | 一种功能蛋白活性的检测方法 |
| EP4486881A1 (en) | 2022-03-01 | 2025-01-08 | Celyntra Therapeutics SA | Composition and methods for transgene insertion |
| CN114796483B (zh) * | 2022-06-28 | 2022-11-08 | 北京大学 | 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物 |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| CN120091827A (zh) | 2022-11-10 | 2025-06-03 | 昂克医疗有限公司 | 使用免疫调节药物的联合疗法 |
| CN116590237B (zh) * | 2023-05-29 | 2023-10-31 | 上海贝斯昂科生物科技有限公司 | 一种遗传修饰的自然杀伤细胞及其制备和用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE531789T1 (de) | 2000-06-30 | 2011-11-15 | Univ Louisville Res Found | Zellmembranenveränderung |
| CA2388441A1 (en) | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
| JP2008505071A (ja) * | 2004-07-02 | 2008-02-21 | アヴァリス・アクチエボラーグ | 細胞を遺伝学的に活性化する方法、および、該細胞の使用 |
| ES2678094T3 (es) | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| EP1621550A1 (en) * | 2004-07-29 | 2006-02-01 | Dompé S.P.A. | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| GB0724532D0 (en) * | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP2595637B1 (en) | 2010-07-22 | 2017-11-01 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
| CN102908612A (zh) * | 2011-08-02 | 2013-02-06 | 北京诺赛基因组研究中心有限公司 | TRAIL截短型变异体活化NF-κB和在炎症反应中的应用 |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| WO2014134351A2 (en) * | 2013-02-27 | 2014-09-04 | The Broad Institute, Inc. | T cell balance gene expression, compositions of matters and methods of use thereof |
| WO2015012145A1 (ja) | 2013-07-25 | 2015-01-29 | 株式会社ブリヂストン | 防振装置 |
| SG11201601283PA (en) * | 2013-08-22 | 2016-03-30 | Queensland Inst Med Res | Immunoreceptor modulation for treating cancer and viral infections |
| AU2014337385B2 (en) * | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Chimeric antigen receptor T cell switches and uses thereof |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| SG11201608701QA (en) | 2014-04-18 | 2016-11-29 | Editas Medicine Inc | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってｎｋ細胞の機能性を改善する方法 |
| US10829735B2 (en) * | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| EP3828266B1 (en) * | 2015-07-29 | 2022-11-23 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US20200392458A1 (en) * | 2017-11-24 | 2020-12-17 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines targetting tumour cells |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
-
2016
- 2016-07-28 EP EP21152473.1A patent/EP3828266B1/en active Active
- 2016-07-28 AU AU2016300128A patent/AU2016300128B2/en not_active Ceased
- 2016-07-28 ES ES18194107T patent/ES2876938T3/es active Active
- 2016-07-28 EP EP20213303.9A patent/EP3971284B1/en active Active
- 2016-07-28 EP EP16750677.3A patent/EP3317401B1/en active Active
- 2016-07-28 CA CA3156128A patent/CA3156128A1/en active Pending
- 2016-07-28 CN CN202210987123.3A patent/CN116064400B/zh active Active
- 2016-07-28 BR BR112018001660-8A patent/BR112018001660A2/pt not_active Application Discontinuation
- 2016-07-28 KR KR1020187005673A patent/KR20180028530A/ko not_active Ceased
- 2016-07-28 JP JP2018524548A patent/JP6974681B2/ja active Active
- 2016-07-28 DK DK18194107.1T patent/DK3434762T3/da active
- 2016-07-28 ES ES18187137T patent/ES2890859T3/es active Active
- 2016-07-28 CN CN201680049392.8A patent/CN108026512B/zh not_active Expired - Fee Related
- 2016-07-28 ES ES20213303T patent/ES2970269T3/es active Active
- 2016-07-28 HK HK18111896.2A patent/HK1252582B/en not_active IP Right Cessation
- 2016-07-28 CA CA2993796A patent/CA2993796C/en active Active
- 2016-07-28 WO PCT/EP2016/068001 patent/WO2017017184A1/en not_active Ceased
- 2016-07-28 DK DK16750677.3T patent/DK3317401T3/da active
- 2016-07-28 EP EP18194107.1A patent/EP3434762B1/en active Active
- 2016-07-28 EP EP21152246.1A patent/EP3878951A1/en not_active Withdrawn
- 2016-07-28 EP EP18187137.7A patent/EP3421590B1/en active Active
- 2016-07-28 ES ES21152473T patent/ES2939084T3/es active Active
- 2016-07-28 CN CN202211000656.4A patent/CN116064401A/zh active Pending
- 2016-07-28 DK DK18187137.7T patent/DK3421590T3/da active
- 2016-07-28 MX MX2018001074A patent/MX380813B/es unknown
- 2016-07-28 ES ES16750677T patent/ES2701338T3/es active Active
-
2017
- 2017-01-12 US US15/405,163 patent/US10034925B2/en active Active
-
2018
- 2018-01-24 MX MX2020010014A patent/MX2020010014A/es unknown
- 2018-07-11 US US16/032,626 patent/US10960064B2/en active Active
-
2020
- 2020-11-30 US US17/107,696 patent/US20210138051A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112020A patent/JP7359346B2/ja active Active
- 2021-07-06 JP JP2021112019A patent/JP2021178824A/ja active Pending
-
2022
- 2022-05-18 AU AU2022203339A patent/AU2022203339A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Sousa Linhares et al. | Not all immune checkpoints are created equal | |
| Gogishvili et al. | SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes | |
| Stecher et al. | PD-1 blockade promotes emerging checkpoint inhibitors in enhancing T cell responses to allogeneic dendritic cells | |
| Minetto et al. | Harnessing NK cells for cancer treatment | |
| Braud et al. | LLT1-CD161 interaction in cancer: promises and challenges | |
| De Andrade et al. | DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins | |
| Hahn et al. | The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 | |
| Beldi-Ferchiou et al. | Control of NK cell activation by immune checkpoint molecules | |
| Cifaldi et al. | DNAM-1 activating receptor and its ligands: how do viruses affect the NK cell-mediated immune surveillance during the various phases of infection? | |
| JP2018520679A5 (enExample) | ||
| Köhler et al. | The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation | |
| Sarkar et al. | Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A | |
| Nabekura et al. | Antigen-specific expansion and differentiation of natural killer cells by alloantigen stimulation | |
| Kaweme et al. | Optimizing NK cell-based immunotherapy in myeloid leukemia: abrogating an immunosuppressive microenvironment | |
| Introna et al. | Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms | |
| Peng et al. | A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| Sungur et al. | Murine natural killer cell licensing and regulation by T regulatory cells in viral responses | |
| Giuliani et al. | Novel targets for the treatment of relapsing multiple myeloma | |
| Konnai et al. | Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus | |
| Nelson et al. | Novel immunotherapies for hematologic malignancies | |
| JP2021503954A5 (enExample) | ||
| Meazza et al. | XLP 1 inhibitory effect by 2 B 4 does not affect DNAM‐1 and NKG 2 D activating pathways in NK cells | |
| Miyakoda et al. | Metformin promotes the protection of mice infected with Plasmodium yoelii independently of γδ T cell expansion | |
| Kumar et al. | The role of co-stimulatory/co-inhibitory signals in graft-vs.-host disease |